Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Restructuring Costs: 2022-2024

Historic Restructuring Costs for InMed Pharmaceuticals (INM) over the last 3 years, with Jun 2024 value amounting to $162,200.

  • InMed Pharmaceuticals' Restructuring Costs rose 229.36% to $104,969 in Q2 2024 from the same period last year, while for Jun 2024 it was $43,726, marking a year-over-year change of. This contributed to the annual value of $162,200 for FY2024, which is 187.55% up from last year.
  • As of FY2024, InMed Pharmaceuticals' Restructuring Costs stood at $162,200, which was up 187.55% from $56,408 recorded in FY2023.
  • InMed Pharmaceuticals' 5-year Restructuring Costs high stood at $289,594 for FY2022, and its period low was $56,408 during FY2023.
  • In the last 3 years, InMed Pharmaceuticals' Restructuring Costs had a median value of $162,200 in 2024 and averaged $169,401.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Restructuring Costs plummeted by 80.52% in 2023, and later skyrocketed by 187.55% in 2024.
  • Over the past 3 years, InMed Pharmaceuticals' Restructuring Costs (Yearly) stood at $289,594 in 2022, then slumped by 80.52% to $56,408 in 2023, then spiked by 187.55% to $162,200 in 2024.